Oneness Biotech Co., Ltd.

BDL:ONEA Stock Report

Market Cap: US$1.3b

Oneness Biotech Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Shuling Cheng

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure3.3yrs

Recent management updates

No updates

Recent updates

CEO

Shuling Cheng

less than a year

Tenure

Dr. Shuling Cheng, Ph. D., served as Chief Strategy Officer of Medeon Biodesign Inc. until 2020. Dr. Cheng served as Vice President of Research and Development at Medeon Biodesign, Inc. and served as its D...

Leadership Team

NamePositionTenureCompensationOwnership
Nien-Yi Chen
Deputy General Manager of Antibody New Drug Division;no dataNT$6.03m0.076%
$ 974.1k
Shuling Cheng
Presidentless than a yearno datano data
Ting-Fang Chen
Financial Officer & Acting Spokespersonless than a yearno datano data
Ai-Chia Yu
Accounting Officerless than a yearno datano data
Wen Ci Xiao
Accounting Supervisorless than a yearno datano data
Jui-Ching Chen
Director of New Drug Development Departmentno datano datano data
Kung-Ming Lu
Director of Operation Centerno datano datano data
Tzu-Chun Yang
Associate General Manager of Information Technology Departmentno dataNT$2.14mno data

0.3yrs

Average Tenure

Experienced Management: ONEA's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Yi-Fu Lin
Director2.6yrsno datano data
Tu-Mu Kuo
Directorless than a yearno datano data
Suei Lu
Independent Director6.5yrsNT$289.00kno data
Jui-Wen Huang
Independent Director9.5yrsNT$289.00kno data
Hsien-Shou Kuo
Chairman14.7yrsNT$22.00k0.0024%
$ 31.1k
San-Kuei Huang
Independent Director3.3yrsNT$181.00kno data
Rey-Yuh Wu
Independent Director3.3yrsNT$126.00kno data

3.3yrs

Average Tenure

Experienced Board: ONEA's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 19:31
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oneness Biotech Co., Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yenya KuoCapital Securities Corporation
Jianzheng WuCapital Securities Corporation
Regina LeeJih Sun Securities Investment Consulting Co., Ltd.